Department of Defense Chemical Biological and Medical Systems Continues Funding Under Development Contract With Cleveland BioLabs for Entolimod(TM) (CBLB502)

Department of Defense Chemical Biological and Medical Systems Continues Funding Under Development Contract With Cleveland BioLabs for Entolimod(TM) (CBLB502)

[at noodls] – Download PDF BUFFALO, N.Y., Oct. 25, 2012 (GLOBE NEWSWIRE) — Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the U.S. Department of Defense (DoD) Chemical Biological and Medical Systems (CBMS) … more

View todays social media effects on CBLI

View the latest stocks trending across Twitter. Click to view dashboard

Share this post